Novogen Limited

Press Releases

2014-December-19	Novogen Raises an Additional A$1.75m in Private Placement to US Institutions for Aggregate Private Placement of A$5.85m (in PDF)
2014-December-17	Novogen Raises A$4.1m in Private Placement to US Institutions (in PDF)
2014-December-16	Novogen Announces Breakthrough Discovery in the Treatment of Melanoma (in PDF)
2014-December-12	Novogen Provides Update on Progress of Cantrixil into the Clinic (in PDF)
2014-December-5	Dr Graham Kelly Discusses Novogen's Cantrixil Program (in PDF)
2014-December-4	Novogen Receives $1.54M R&D Tax Incentive (in PDF)
2014-November-24	Novogen Announces Exciting New Drug Candidate Targeting Children's Solid Tumors and Other Adult Cancers (in PDF)
2014-November-21	Novogen Announces Identification of Lead ATM Drug Candidate (in PDF)
2014-November-20	Mr Iain Ross Resigns as Non-Executive Director (in PDF)
2014-November-18	CEO Report on the AGM and the Future (in PDF)
2014-November-12	Novogen Receives NASDAQ Deficiency Notice (in PDF)
2014-November-12	Annual General Meeting - Chairman's Address (in PDF)
2014-November-12	Novogen Announces Close of Capital-Raise & Additional Initiatives to Secure Further Funding (in PDF)
2014-November-7	Extension of the ASX BookBuild Facility (in PDF)
2014-November-6	Cantrixil Proves Highly Effective in Pre-clinical Test of Refractory Ovarian Cancer (in PDF)
2014-November-3	Confirmation of Share Placement Terms (in PDF)
2014-October-31	Clarification of Capital Raise Option Issue Announcement on 16 October 2014 (in PDF)
2014-October-27	Novogen Investor Presentation and Webinar (in PDF)
2014-October-24	Dr Graham Kelly, Novogen CEO Speaks with ShareCafe Reporter James Dunn About the Novogen Pipeline and the Current Capital Raise (in PDF)
2014-October-22	Novogen Announces Appointment of TLM for its ASX Bookbuild and Webinar (in PDF)
2014-October-22	Live Web Streaming Details - Novogen Capital Raising Investor Presentation and Q&A Session (in PDF)
2014-October-22	Studies Confirm Potential of Trilexium for Childhood Cancers (in PDF)
2014-October-17	Information Memorandum (in PDF)
2014-October-16	Novogen Announces Capital-Raising via ASX Bookbuild Facility (in PDF)
2014-October-1	FDA Provides Guidance on the Clinical Development of Cantrixil (in PDF)
2014-September-29	ABC TV Interview Discusses the Potential of Trilexium™ to Treat Brain Cancer (in PDF)
2014-September-10	NRT Dr Kelly Interview (in PDF)
2014-September-9	Novogen Dr Stephen Palmer Speaks at Annual FSHD Research Meetings in Australia (in PDF)
2014-September-4	Novogen Announces Presentation at Rodman & Renshaw 16th Annual Healthcare Conference (in PDF)
2014-August-13	Novogen Announces Results of General Meeting of Shareholders (in PDF)
2014-August-12	Grant Approval to Commence Studies in Muscular Dystrophy (in PDF)
2014-August-11	Novogen Organises a Meeting to Summarise Future Strategies (in PDF)
2014-July-25	Appointment of Contract Manufacturers to Produce Cantrixil (in PDF)
2014-June-18	Potency of Trx-1 Confirmed Against Ovarian Cancer Stem Cells (in PDF)
2014-May-27	Identification of Highly Active Drug Against Prostate Cancer (in PDF)
2014-May-5	Novogen Presentation at Cavendish Global Available Online (in PDF)
2014-May-5	Novogen Join's Children Oncology Drug Alliance (CODA) (in PDF)
2014-May-2	Novogen Announces Partnership with Genea Biocells (in PDF)
2014-March-18	Novogen and CanTx Experimental Drug Proves Effective in Vivo (in PDF)
2014-March-13	Novogen to Present at Annual Sachs Cancer Bio Forum in NY (in PDF)
2014-March-11	Novogen Selected to Present at Cavendish Global Health Forum (in PDF)
2014-March-5	Novogen Appoints New Directors and Strategic Advisor (in PDF)
2014-February-3	Key Appointments to Drive the Anti-Tropomyosin Drug Platform (in PDF)
2014-January-31	Novogen to Host Corporate Update Meeting and Webcast (in PDF)
2015	2015 Press Releases
2013	2013 Press Releases